MOUNJARO® 10mg KwikPen®, 1 Stk.

MOUNJARO® 10mg KwikPen® is a prefilled, multi-dose pen containing 10 mg tirzepatide per 0.6 mL injection. The full pen holds 40 mg in 2.4 mL (approx. 16.7 mg/mL) and is designed for weekly subcutaneous dosing. This therapy acts on GIP and GLP-1 receptors and is indicated for both blood sugar management in type 2 diabetes and weight control. The solution is clear, colourless to faint yellow.

• Injection strength: 10 mg/0.6 mL

• Pen volume: 40 mg/2.4 mL

• Concentration: 16.7 mg/mL

• Mechanism: Dual incretin agonist (GIP & GLP-1)

• Sites: Stomach, thigh, upper arm

The pen provides a weekly subcutaneous dose, following gradual titration to minimize side effects.

• Stepwise dosing: Begin with 2.5 mg weekly, escalate every 4 weeks until reaching 10 mg

• Maintenance options: 5 mg, 10 mg, or 15 mg; 10 mg is a standard maintenance dose

• Weekly routine: Same day weekly; may adjust if ≥3 days apart

• Missed injection: If <4 days late, inject promptly; if >4 days, skip

• Injection: Dial to 1, inject 0.6 mL, hold 5 sec, confirm dose window reset

• Rotate injection sites to reduce skin irritation

Prescribed for adults with insufficiently controlled type 2 diabetes and for chronic weight management. Always combined with lifestyle interventions.

• Diabetes care: As single agent or combined with other glucose-lowering therapies

• Obesity treatment: Adults with BMI ≥30, or ≥27 with comorbid conditions

• Contraindicated in: Allergy to tirzepatide/excipients

• Cautions: Not studied in severe GI disease or advanced diabetic eye disease

• Pregnancy: Discontinue before conception (≥1 month in advance)

• Typical side effects: GI upset, decreased appetite, occasional hypoglycaemia (esp. with insulin/secretagogues)

Formulated as a clear injectable solution, delivering 10 mg tirzepatide with each 0.6 mL dose.

• Active drug: Tirzepatide 10 mg

• Full pen: 40 mg/2.4 mL solution

• Concentration: 16.7 mg/mL

• Excipients: Contains benzyl alcohol and buffer components

• Sodium level: Essentially sodium-free

Each retail unit includes the pen and instructions, but no needles.

• Pen device: Multi-use KwikPen (4 weekly doses)

• Documentation: Leaflet + Instructions for Use

• Needles: Not included

Yes, the most reported effects involve the digestive tract. These are dose-related and generally diminish with time.

• GI adverse events: Nausea, diarrhoea, constipation; up to 39% incidence at 10 mg

• Hypoglycaemia: Notable risk if combined with sulphonylurea or insulin

• Injection-site reactions: ~5% in studies

• Gallbladder events: Reported but uncommon

• Rare risks: Acute pancreatitis, hypersensitivity reactions

Proper storage ensures safety and effectiveness. Disposal follows usage schedule.

• Unopened: Refrigerate at 2–8°C

• Do not freeze

• After opening: Keep at ≤30°C, discard after 30 days

• Each pen: Used for 4 doses, then discard

• Always remove needle after injection